50% of patients have been enrolled in a phase Ib study

The study aims to investigate the safety of a medical drug in patients with medium active ulcerative colitis.

This is a multicenter, randomized, double-blind, placebo-controlled, parallel study.

The study participants include healthy male volunteers, ages 18 to 45. The patients will be divided into two therapy groups: the first group will take the investigational drug, while the second group will be given a placebo. Currently, the enrollment of patients for the study is significantly ahead of the planned schedule.

OCT team is responsible for site-management, project management, logistics and quality assurance.

Back to the list